Serum microRNA Profiles Serve as Novel Biomarkers for Autoimmune Diseases. 2018

Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute for Life Sciences, Nanjing University, Nanjing, China.

Autoimmune diseases involve a complex dysregulation of immunity. Autoimmune diseases include many members [e.g., rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)], and most of them are classified according to what organs and tissues are targeted by the damaging immune response. Many studies have focused on finding specific biomarkers for single autoimmune diseases, but so far, there are no universal biomarkers for detecting almost all autoimmune diseases. Serum miRNAs have served as potential biomarkers for detecting various diseases. The purpose of this study was to find a universal biomarker for diagnosing autoimmune diseases. Regulatory T cells (Tregs) play a crucial role in protecting an individual from autoimmunity, and depletion of Tregs in mice is considered a representative animal model of autoimmune disease. Two mouse models for Treg depletion, in which Treg was depleted by CD25mAb (in C57 mice) or by diphtheria toxin (DT) (in Foxp3DTR mice), were investigated, and 381 miRNAs were identified in the serum of mice with Treg depletion. A distinctive circulating miRNA profile was identified in Treg-depleted mice and in patients with autoimmune disease. QRT-PCR confirmation and ROC curve analysis determined that six miRNAs (miR-551b, miR-448, miR-9, miR-124, miR-148, and miR-34c) in the Treg-depleted mouse models and three miRNAs [miR-551b (specificity 73.5%, sensitivity 88.4%), miR-448 (specificity 82.4%, sensitivity 91.3%), and miR-124 (specificity 76.5%, sensitivity 91.3%)] in patients with RA, SLE, Sjogren's syndrome (SS), and ulcerative colitis (UC) could serve as valuable specific biomarkers. These circulating miRNAs may represent potential universal biomarkers for autoimmune diseases diagnosis and prognosis.

UI MeSH Term Description Entries
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008297 Male Males
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074166 Circulating MicroRNA MicroRNAs found in cell-free BODY FLUIDS such as SERUM; PLASMA; SALIVA; OR URINE. Cell-Free MicroRNA,Cell Free MicroRNA,MicroRNA, Cell-Free,MicroRNA, Circulating
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
January 2015, Disease markers,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
December 2010, Cancer research,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
January 2015, PloS one,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
June 2017, Liver international : official journal of the International Association for the Study of the Liver,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
July 2016, Oncotarget,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
January 2012, PloS one,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
February 2015, International journal of cancer,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
July 2014, Molecular biology reports,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
January 2018, Disease markers,
Fangfang Jin, and Huanhuan Hu, and Ming Xu, and Shoubin Zhan, and Yanbo Wang, and Huayong Zhang, and Xi Chen
March 2022, Experimental and therapeutic medicine,
Copied contents to your clipboard!